Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2

NCT ID: NCT03338348

Last Updated: 2020-10-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 9 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-04-19
• Study Completion Date: 2019-10-31

Brief Summary

The main part of this trial is a phase II study of vosaroxin with azacitidine in older patients with newly diagnosed AML and intermediate or adverse genetic risk or MDS-EB-2. An initial safety run-in phase of the study will be performed administering the study drug vosaroxin with azacitidine in up to 18 patients. After completion of the run-in phase, toxicity and response data will be provided to the external Data and Safety Monitoring Board (DSMB) and the Trial Committee by the Coordinating Investigator. The Trial Committee will decide on the basis of these data and the recommendation of the DSMB on dose modification and the vosaroxin dose for the phase II part of the study, which will include 150 patients in total.

Conditions

Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Azacitidine + Vosaroxin

Cycle 1-8:

Azacitidine: 75 mg/m²/d subcutaneously, d 1-7; Vosaroxin: Dose Level 0: 70mg/m², Dose Level -1: 50mg/m², Dose Level -2: 40mg/m², IV over ten minutes, d 1+4 .

Patients who have completed 8 cycles of azacitidine and vosaroxin are scheduled to maintenance with single agent azacitidine at 75 mg/m²/d on days 1-7 until relapse or progression.

Group Type: OTHER

Vosaroxin

Intervention Type: DRUG

Cycle 1-8: Dose Level 0: 70mg/m², Dose Level -1: 50mg/m², Dose Level -2: 40mg/m², IV over ten minutes, d 1+4 .

Azacitidine

Intervention Type: DRUG

Cycle 1-8 Azacitidine: 75 mg/m²/d subcutaneously, d 1-7;

Maintenance with single agent azacitidine at 75 mg/m²/d on days 1-7 until relapse or progression.

Interventions

Vosaroxin

Cycle 1-8: Dose Level 0: 70mg/m², Dose Level -1: 50mg/m², Dose Level -2: 40mg/m², IV over ten minutes, d 1+4 .

Intervention Type: DRUG

Azacitidine

Cycle 1-8 Azacitidine: 75 mg/m²/d subcutaneously, d 1-7;

Maintenance with single agent azacitidine at 75 mg/m²/d on days 1-7 until relapse or progression.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients with confirmed diagnosis of acute myeloid leukemia (WHO 2016) and intermediate or adverse genetic risk (according to 2017 ELN recommendations); or patients with myelodysplastic syndrome with excess blasts-2 (MDS-EB-2)

2. Patients ≥60 years of age

3. No prior chemotherapy for leukemia except hydroxyurea to control hyperleukocytosis for up to 10 days during the diagnostic screening phase; patients may have received prior therapy for myelodysplastic syndrome different from hypomethylating agents

4. ECOG performance status ≤2

5. Men must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy and must agree to avoid to father a child (while on therapy and for 3 month after the last dose of vosaroxin)

6. Non-pregnant and non-nursing women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL within 72 hours prior to registration ("Women of childbearing potential" is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months).

7. Female patients of reproductive age must agree to avoid getting pregnant while on therapy and for 3 months after the last dose of vosaroxin.

8. Women of child-bearing potential including the female partners of the male patients must either commit to continued abstinence from heterosexual intercourse or apply two acceptable methods of birth control (IUD, tubal ligation, or partner's vasectomy). Hormonal contraception is an inadequate method of birth control.

9. Men must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy (while on therapy and for three months after the last dose of chemotherapy)

10. Willing to adhere to protocol specific requirements

11. Following receipt of verbal and written information about the study, the patient must provide signed informed consent before any study related activity is carried out

Exclusion Criteria

1. Known or suspected hypersensitivity to the study drugs and/or any excipients

2. Favorable genetics: t(15;17)(q22;q12), PML-RARA; t(8;21)(q22;q22), RUNX1-RUNX1T1; inv(16)(p13.1q22)/t(16;16)(p13.1;q22), CBFB-MYH11; mutated NPM1 without FLT3-ITD or with FLT3-ITDlow

3. Prior treatment for AML except hydroxyurea

4. Prior treatment for MDS with hypomethylating agents

5. ECOG performance status >2

6. Patients who are not eligible for intensive chemotherapy

7. Inadequate cardiac, hepatic and/or renal function at the Screening Visit defined as:

• Ejection fraction <40% confirmed by echocardiography
• Creatinine >1.5x upper normal serum level
• Total bilirubin, AST or ALT >1.5 upper normal serum level

8. Active central nervous system involvement

9. Any clinically significant, advanced or unstable disease or history of that may interfere with primary or secondary variable evaluations or put the patient at special risk, such as:

• Myocardial infarction, unstable angina within 3 months before screening
• Heart failure NYHA III/IV
• Severe obstructive or restrictive ventilation disorder
• Uncontrolled infection

10. Severe neurological or psychiatric disorder interfering with ability of giving an informed consent

11. Currently receiving a therapy not permitted during the study, as defined in Section 10.5.4

12. Patients with a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year.

13. Known history of positive test for Hepatitis B surface Antigen (HBsAg) or hepatitis C antibody or history of positive test for Human Immunodeficiency Virus (HIV)

14. Hematological disorder independent of leukemia

15. No consent for registration, storage and processing of the individual disease characteristics and course as well as information of the family physician and/or other physicians involved in the treatment of the patient about study participation

16. No consent for biobanking

17. Current participation in any other interventional clinical study within 30 days before the first administration of the investigational product or at any time during the study

18. Patients known or suspected of not being able to comply with this trial protocol

19. Patients of childbearing potential not willing to use adequate contraception during study and 3 months after last dose of therapy

20. Breast feeding women or women with a positive pregnancy test at Screening visit

• Minimum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sunesis Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

University of Ulm

OTHER

Sponsor Role: lead

Responsible Party

Verena Gaidzik

Prinicipal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Kliniken Essen-Süd, Evang. Krankenhaus Essen-Werden gGmbH

Essen, , Germany

Klinikum Oldenburg, Klinik für Innere Medizin II

Oldenburg, , Germany

University Hospital Ulm

Ulm, , Germany

Countries

Germany

Other Identifiers

AMLSG 24-15

Identifier Type: -

Identifier Source: org_study_id